Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer, February 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 279 articles: HTML format

Single Articles

1. RAHMADI R, Mudhia Arisa Putri U, Herman H, Rachman W, et al
   Case Report: Radical urethrectomy with partial cystectomy and bladder outlet reconstruction in giant female urethral adenocarcinoma infiltrating the bladder: A rare case report.
   F1000Res. 2026;14:741.
   PubMed    
   Abstract available
   
   

2. ZHANG X, Zong R, Sun Y, Chen N, et al
   The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling.
   Oncol Res. 2026;34:21.
   PubMed    
   Abstract available
   
   

3. FENG R, Zhang J, Tao Y, Hou J, et al
   Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
   Front Oncol. 2026;15:1644747.
   PubMed    
   Abstract available
   
   

4. CHEN ST, Chang KS, Hou CP, Lin WY, et al
   WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells.
   Transl Oncol. 2026;65:102680.
   PubMed    
   Abstract available
   
   

5. NEBIOGLU A, Basaranoglu M, Bozlu M, Tek M, et al
   Effects of dutasteride with Bacillus Calmette-Guerin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study.
   BMC Urol. 2026 Jan 28. doi: 10.1186/s12894-026-02059.
   PubMed    
   
   
   

6. LU Q, Guo J, Xu Y, Cui Y, et al
   RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.
   Discov Oncol. 2026 Jan 28. doi: 10.1007/s12672-026-04514.
   PubMed    
   
   
   

7. MARCQ G, Dahm P, Maisch P
   En-bloc resection: Evidence and uncertainty Re: Comparative effectiveness of en-bloc resection techniques vs. conventional transurethral resection for non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
   Can Urol Assoc J. 2026;20:E80-E81.
   PubMed    
   
   
   

8. SHIH YC, Wu CY, Huang SW, Tsai CY, et al
   Multimodal Large Language Models for Cystoscopic Image Interpretation and Bladder Lesion Classification: Comparative Study.
   J Med Internet Res. 2026;28:e87193.
   PubMed    
   Abstract available
   
   

9. SHI WY, Liu KJ, Esfahani MS, Mach KE, et al
   Field-effect-informed urine liquid biopsy for bladder cancer.
   Cell. 2026 Jan 27:S0092-8674(25)01503-X. doi: 10.1016/j.cell.2025.
   PubMed    
   Abstract available
   
   

10. SCHERRER M, Brunaiova L, Furrer M, John H, et al
    How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database.
    World J Urol. 2026;44:133.
    PubMed    
    Abstract available
    
    

11. HE Y, Xie J, Zhong S, Zhan C, et al
    A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder Cancer.
    Research (Wash D C). 2026;9:1053.
    PubMed    
    Abstract available
    
    

12. HU H, Huang J, Ma L, Zhang S, et al
    Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.
    Front Urol. 2026;5:1713128.
    PubMed    
    Abstract available
    
    

13. PAN S, Cui W, Lin J, Wang Z, et al
    The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.
    Front Immunol. 2026;16:1716230.
    PubMed    
    Abstract available
    
    

14. FRYD ND, Albertsen N, Bernth-Andersen S, Ernst A, et al
    The GreenBladder Study: Early Detection of Bladder Cancer in Greenland Using a Urinary Biomarker.
    J Clin Med. 2026;15:761.
    PubMed    
    Abstract available
    
    

15. KLATTE T, Bold F, Dengler J, de Martino M, et al
    Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network.
    Life (Basel). 2026;16:169.
    PubMed    
    Abstract available
    
    

16. ALQAISI O, Tai P, Storme G
    Specialized Nursing-Led Interventions for Bladder Cancer Management: A Scoping Review of Evidence and Clinical Outcomes.
    Medicina (Kaunas). 2026;62:185.
    PubMed    
    Abstract available
    
    

17. NEBIOGLU A, Turhan A, Basaranoglu M, Bozlu M, et al
    Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.
    Medicina (Kaunas). 2025;62:51.
    PubMed    
    Abstract available
    
    

18. COJOCARU I, Guliciuc M, Cojocaru E, Serban C, et al
    A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Medicina (Kaunas). 2025;62:46.
    PubMed    
    Abstract available
    
    

19. JIANG H, Chen Y, Zeng X, Yang R, et al
    The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.
    Int J Mol Sci. 2026;27:596.
    PubMed    
    Abstract available
    
    

20. MOHAMED AA, AbdulAzeem Y, Almudaifer AI, ZainEldin H, et al
    Explainable Computational Imaging for Precision Oncology: An Interpretable Deep Learning Framework for Bladder Cancer Histopathology Diagnosis.
    Bioengineering (Basel). 2025;13:4.
    PubMed    
    Abstract available
    
    

21. NAN Z, Zhao W, Li S, Yue C, et al
    Unequal Progress in Early-Onset Bladder Cancer Control: Global Trends, Socioeconomic Disparities, and Policy Efficiency from 1990 to 2021.
    Healthcare (Basel). 2026;14:193.
    PubMed    
    Abstract available
    
    

22. CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
    Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer.
    Cancers (Basel). 2026;18:308.
    PubMed    
    Abstract available
    
    

23. PACKIAM VT, Ghodoussipour S, Konety BR, Ahmadi H, et al
    Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study.
    Cancers (Basel). 2026;18:249.
    PubMed    
    Abstract available
    
    

24. PITOUT A, Mazeaud C, Blondeau A, Salleron J, et al
    Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study.
    Cancers (Basel). 2026;18:222.
    PubMed    
    Abstract available
    
    

25. SANDHU K, Hopkins DT, Newton M, Sathianathen N, et al
    Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.
    Cancers (Basel). 2026;18:189.
    PubMed    
    Abstract available
    
    

26. PIRES I, Files R
    Silent Threats: A Narrative Review of Urinary Bladder Cancer in Dogs and Cats-Epidemiology and Risk Factors.
    Animals (Basel). 2026;16:217.
    PubMed    
    Abstract available
    
    

27. MIKI J, Kimura S, Urabe F, Atsuta M, et al
    Optimizing pelvic lymph node dissection in bladder cancer: obturator focus, pN1 prognosis, and sentinel node feasibility.
    Int J Clin Oncol. 2026 Jan 27. doi: 10.1007/s10147-026-02969.
    PubMed    
    Abstract available
    
    

28. SHEN L, Yu C, Wu Y, Chen H, et al
    NFIB suppresses cell migration, invasion and EMT of bladder cancer through the PI3K-AKT signaling pathway.
    Cytotechnology. 2026;78:33.
    PubMed    
    Abstract available
    
    

29. QIU M, Zhang S, Liang J, Chen G, et al
    Prolyl 4-Hydroxylase Beta Peptide Promotes Invasion, Migration, and Epithelial-Mesenchymal Transition through Activation of the Claudin-1/ AMPK/TGF-beta1 Pathway in Bladder Cancer Cells.
    Protein Pept Lett. 2026 Jan 22. doi: 10.2174/0109298665418763251124051527.
    PubMed    
    Abstract available
    
    

30. ZENG D, Liu B, Deng F, Wang Y, et al
    Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.
    Oncologist. 2026;31:oyaf409.
    PubMed    
    Abstract available
    
    

31. SILVA TA, Viana LG, Carvalho VM, Bertolla RP, et al
    Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk.
    J Proteome Res. 2026 Jan 26. doi: 10.1021/acs.jproteome.5c00486.
    PubMed    
    Abstract available
    
    

32. WANG X, Preston A, Aning J, Loizou M, et al
    Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.
    IEEE Trans Biomed Eng. 2026;PP.
    PubMed    
    Abstract available
    
    

33. KARKEET RM, Sayed-Ahmed MM, Ghaly S, Farouk M, et al
    Comprehensive Evaluation of Bacillus Calmette-Guerin therapy in Non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study.
    J Egypt Natl Canc Inst. 2026;38:2.
    PubMed    
    
    
    

34. ZHANG WW, Qu HR, Du XS, Sun SJ, et al
    SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression.
    Cell Oncol (Dordr). 2026;49:30.
    PubMed    
    Abstract available
    
    

35. NAPPI A, Crocetto F, Conforti P, Sagliocchi S, et al
    Cell-free RNA profiling uncovers non-canonical circulating D2 transcript elevation in Bladder Cancer plasma.
    J Liq Biopsy. 2026;11:100454.
    PubMed    
    Abstract available
    
    

36. WANG P, Deng J, Wu S
    Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.
    Front Oncol. 2026;15:1579873.
    PubMed    
    Abstract available
    
    

37. HARMON JF, Santos E, Johnson-Pais TL, Leach RJ, et al
    Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population.
    Bladder Cancer. 2026;12:23523735261417401.
    PubMed    
    Abstract available
    
    

38. SU X, Yu H, Zhang M, Zeng K, et al
    A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness.
    Front Mol Biosci. 2026;12:1716130.
    PubMed    
    Abstract available
    
    

39. YUAN Z, Situ M, Ye Y, Zhang J, et al
    Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.
    Front Immunol. 2026;16:1730356.
    PubMed    
    Abstract available
    
    

40. CHAN CC, Lee MJ, Su J, Su JJ, et al
    Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer.
    Pharmacol Res Perspect. 2026;14:e70212.
    PubMed    
    Abstract available
    
    

41. CHEN Y, Lao M, Shen M, Wang Z, et al
    TMIGD2 in Bladder Cancer: A Bioinformatics and Experimental Approach to Understanding its Prognostic and Therapeutic Potential.
    Curr Top Med Chem. 2026 Jan 15. doi: 10.2174/0115680266414071251126071447.
    PubMed    
    Abstract available
    
    

42. CHEN Y, Zhu H, Lao M, Ding G, et al
    Exploring ZPLD1 as a Prognostic Indicator and Therapeutic Target in Bladder Cancer.
    Curr Med Chem. 2026 Jan 15. doi: 10.2174/0109298673413898251122184011.
    PubMed    
    Abstract available
    
    

43. FANG Q, You C, Xiao X, Yang W, et al
    Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.
    Int J Biol Macromol. 2026;343.
    PubMed    
    Abstract available
    
    

44. LUTY M, Szydlak R, Pabijan J, Ovreeide IH, et al
    Identification of glycosylation-related changes in migratory and mechanical properties of bladder cancer cells.
    Biosens Bioelectron. 2026;298:118410.
    PubMed    
    Abstract available
    
    

45. CHEN M, Zheng L, Huang D, Wang S, et al
    RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.
    Int J Biol Macromol. 2026 Jan 22:150142. doi: 10.1016/j.ijbiomac.2026.150142.
    PubMed    
    Abstract available
    
    

46. CHEN Q, Wu R, Zhang C, Xie J, et al
    Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study.
    Urol Oncol. 2026;44:110988.
    PubMed    
    Abstract available
    
    

47. KLUTH M, Plage H, Furlano K, Hofbauer S, et al
    PTEN Deletions Are Associated With Tumor Progression But Unrelated to Patient Prognosis in Muscle-Invasive Urothelial Bladder Carcinomas: A Large Multi-Center Validation Study on 2710 Urothelial Bladder Carcinomas.
    Genes Chromosomes Cancer. 2026;65:e70105.
    PubMed    
    Abstract available
    
    

48. CHEN WW, Wu B, Wen X
    Causal association between socioeconomic disparities and tumors of the urinary system: A Mendelian randomization study.
    Medicine (Baltimore). 2026;105:e47216.
    PubMed    
    Abstract available
    
    

49. WANG Y, Bhandary P, Moore JH, Li X, et al
    Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer.
    Biol Sex Differ. 2026 Jan 23. doi: 10.1186/s13293-026-00829.
    PubMed    
    Abstract available
    
    

50. BENTSEN L, Lund-Jacobsen T, Jakobsen CB, Larsen FM, et al
    Shared Decision-Making in Curative Uro-Oncology: A Systematic Review.
    Semin Oncol Nurs. 2026;42:152116.
    PubMed    
    Abstract available
    
    

51. SONG T, He W, Yuan Q, Xia S, et al
    ADAM12-programmed ECM-CAF remodeling activates PI3K-AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance.
    Cell Signal. 2026 Feb 4:112398. doi: 10.1016/j.cellsig.2026.112398.
    PubMed    
    Abstract available
    
    

52. LABROY M, Chabaud S, Durand M, Fourquaux I, et al
    Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.
    Transl Oncol. 2026;65:102687.
    PubMed    
    Abstract available
    
    

53. WANG Y, Ni H, Dong S, Shang Y, et al
    Environmental Dose MEOHP Promotes Bladder Cancer Progress through Hybrid EMT Mechanism: Based on the Adverse Outcome Pathway.
    Environ Sci Technol. 2026 Feb 6. doi: 10.1021/acs.est.5c08003.
    PubMed    
    Abstract available
    
    

54. JIANG M, Sun C, Wang B, Huang Q, et al
    Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study.
    Medicine (Baltimore). 2026;105:e47378.
    PubMed    
    Abstract available
    
    

55. TAKADA H, Ikeda M, Tanaka R, Samejima N, et al
    Prognostic effect of preoperative albumin-to-globulin ratio in patients with non-metastatic bladder cancer undergoing radical cystectomy.
    Oncology. 2026 Feb 6:1-20. doi: 10.1159/000550892.
    PubMed    
    Abstract available
    
    

56. MEHMUD I, Zhang Y, Wu S, Zhang S, et al
    Oncological Safety of Bladder Preservation in Elderly Patients with Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2026 Feb 6. doi: 10.1245/s10434-025-19064.
    PubMed    
    Abstract available
    
    

57. BOLENZ C, Zengerling F, Kubler H, Hahn O, et al
    [Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?].
    Urologie. 2026 Feb 6. doi: 10.1007/s00120-026-02774.
    PubMed    
    Abstract available
    
    

58. MOJICA W, Izydorczak A, Wood T, Hsu J, et al
    A Novel Method to Generate Analyte-Specific Specimens for Multi-Omic Studies of Primary Bladder Cancer.
    Biopreserv Biobank. 2026 Feb 6:19475535251394594. doi: 10.1177/19475535251394594
    PubMed    
    Abstract available
    
    

59. NING W, Chang P, Zheng J, Chen W, et al
    Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.
    Front Immunol. 2026;16:1684597.
    PubMed    
    Abstract available
    
    

60. GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
    Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
    medRxiv [Preprint]. 2026 Jan 16:2026.01.14.26344033.
    PubMed    
    Abstract available
    
    

61. JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
    Understanding Bladder Cancer Screening Limits Through Comparative Modeling: The Maximum Clinical Incidence Reduction (MCLIR) Methodology.
    medRxiv [Preprint]. 2026 Jan 30:2026.01.27.26344939.
    PubMed    
    Abstract available
    
    

62. MAK KS, Efstathiou JA
    Tipping the Scales for Bladder Cancer: Weighing Differences in Quality of Life After Cystectomy Versus Trimodality Therapy.
    Int J Radiat Oncol Biol Phys. 2026;124:651-653.
    PubMed    
    
    
    

63. NABIYOUNI F, Chiou PZ
    Enhancing urine cytopathology with artificial intelligence: a systematic review.
    Am J Clin Pathol. 2026;165:aqaf135.
    PubMed    
    Abstract available
    
    

64. LIU N, Xing L, Chen H, Chen S, et al
    Sequential dilatation of two balloons and double D-J stents for therapy of ureteroenteral anastomotic stricture in patients following radical cystectomy and Bricker urinary diversion.
    Afr Health Sci. 2025;25:334-342.
    PubMed    
    Abstract available
    
    

65. CHEN K, Su H, Pei F, Chen X, et al
    KNTC1 initiates a KNTC1/E2F8/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer.
    J Exp Clin Cancer Res. 2026 Feb 4. doi: 10.1186/s13046-026-03651.
    PubMed    
    
    
    

66. HSIEH YC, Li CF, Ho CH, Huang SK, et al
    Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Appl Immunohistochem Mol Morphol. 2026 Feb 5. doi: 10.1097/PAI.0000000000001307.
    PubMed    
    Abstract available
    
    

67. JIN H
    Comment on "adjuvant bacillus Calmette-Gu'erin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study".
    Int Immunopharmacol. 2026;173:116312.
    PubMed    
    
    
    

68. XU G, Li Y, Peng S, Zhao W, et al
    Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer.
    Cell Rep. 2026;45:116941.
    PubMed    
    Abstract available
    
    

69. LIU Q, Lu X, He C, Chen J, et al
    A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
    Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19122.
    PubMed    
    Abstract available
    
    

70. WANG Y, Guo S, Zeng J, Feng W, et al
    Prognostic Significance of Lymph Node Ratio for Overall Survival in Patients with Lymph Node-Positive Bladder Cancer Post-Radical Cystectomy and Chemotherapy: A Multicenter Cohort Analysis.
    Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19090.
    PubMed    
    Abstract available
    
    

71. DE FELICE M, Tammaro M, Caterino M, Nacca V, et al
    Fulminant Fournier gangrene in bladder cancer: case report and review of the literature.
    Eur Rev Med Pharmacol Sci. 2026;30:46-50.
    PubMed    
    Abstract available
    
    

72. OZTURK YUZDEMIR K, User IR, Ozcan HN, Orhan D, et al
    Pediatric inflammatory myofibroblastic tumor of the urinary bladder: a rare case report and treatment approach.
    Turk J Pediatr. 2025;67:920-926.
    PubMed    
    Abstract available
    
    

73. SOMA T, Takemura K, Toide M, Ito M, et al
    Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guerin failure: a systematic review.
    BMJ Oncol. 2026;5:e000753.
    PubMed    
    Abstract available
    
    

74. YIN Y, Qin Z, Zhou H, Wu Y, et al
    Ultrasound Responsive Mn/Se-Nanozyme as PANoptosis Initiators for Bladder Cancer Immunotherapy.
    Adv Healthc Mater. 2026 Feb 3:e04808. doi: 10.1002/adhm.202504808.
    PubMed    
    Abstract available
    
    

75. HAJIME T, Shiota M, Matsumoto T, Mutaguchi J, et al
    ASO Author Reflections: Tumor Laterality as a Key Determinant of Pelvic Lymph Node Dissection Strategy in Bladder Cancer.
    Ann Surg Oncol. 2026 Feb 3. doi: 10.1245/s10434-026-19200.
    PubMed    
    
    
    

76. TANG X, Liu L, Gao M, Duan P, et al
    Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer.
    Sci Rep. 2026 Feb 3. doi: 10.1038/s41598-026-38219.
    PubMed    
    
    
    

77. SHEN C, Liu C, Hu D, Ge H, et al
    Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.
    J Immunother Cancer. 2026;14:e013809.
    PubMed    
    Abstract available
    
    

78. ZHANG H, Liu Y, Huang W, Li Y, et al
    Mediator complex subunit 8 promotes bladder cancer progression via Stearoyl-CoA desaturase.
    Cell Mol Life Sci. 2026 Feb 3. doi: 10.1007/s00018-026-06083.
    PubMed    
    
    
    

79. WANG Z, He W, Wang M, Hua M, et al
    Integrated multicenter single-cell atlas of bladder cancer reveals tumor heterogeneity associated with immunotherapy.
    Int J Surg. 2026 Feb 3. doi: 10.1097/JS9.0000000000003830.
    PubMed    
    Abstract available
    
    

80. MIKHAIL AS, Gurram S, Valera VA, Haemmerich D, et al
    Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.
    Int J Hyperthermia. 2026;43:2615462.
    PubMed    
    Abstract available
    
    

81. VAN DE MERBEL AF, van der Mark MH, Hensen LCM, van den Wollenberg DJM, et al
    Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models.
    Mol Ther Oncol. 2026;34:201128.
    PubMed    
    Abstract available
    
    

82. YOUSSEF M, Nasseredine B, Amine Z, Amine S, et al
    Psoas metastasis mimicking abscess in untreated muscle-invasive bladder cancer: A diagnostic pitfall.
    Radiol Case Rep. 2026;21:1554-1558.
    PubMed    
    Abstract available
    
    

83. MENG X, Su CY, Yang Z
    Editorial Comment on: "Enhanced Artificial Intelligence in Bladder Cancer Management: A Comparative Analysis and Optimization Study of Multiple Large Language Models" by Li et al.
    J Endourol. 2026 Feb 2:8927790251387369. doi: 10.1177/08927790251387369.
    PubMed    
    
    
    

84. YAMAMOTO S, Fukata S, Shimasaki S, Kurano Y, et al
    Clinical Outcomes Following Transurethral Laser Ablation with Topical Versus General or Spinal Anesthesia for Non-Muscle-Invasive Bladder Cancer: A Japanese Single-Center Pilot Study.
    Photodiagnosis Photodyn Ther. 2026 Jan 31:105376.
    PubMed    
    Abstract available
    
    

85. YOKOYAMA T, Kobayashi H, Horiguchi A, Miyai K, et al
    A Case of Primary Bladder Neuroendocrine Carcinoma With Urethral Invasion Following Radical Prostatectomy.
    Asian J Endosc Surg. 2026;19:e70251.
    PubMed    
    Abstract available
    
    

86. ZHANG M, Zhou Y
    Sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study.
    Support Care Cancer. 2026;34:151.
    PubMed    
    Abstract available
    
    

87. WANG X, Jin L, Zou X, Zhu A, et al
    ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.
    J Pharm Anal. 2026;16:101519.
    PubMed    
    Abstract available
    
    

88. LIU Z, Zhou C, Xu W, Zhang D, et al
    Polyarginine Peptide R11-Actin Interaction Induces a Domino Effect on Cytoskeleton Remodeling to Suppress Bladder Cancer Metastasis.
    Research (Wash D C). 2026;9:1109.
    PubMed    
    Abstract available
    
    

89. ZHANG M, Lin L, Xu H, Su X, et al
    A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer.
    Front Mol Biosci. 2026;12:1722809.
    PubMed    
    Abstract available
    
    

90. EL OMRI G, Houssaini OI, Rachid M, Houry Y, et al
    Non-functional bladder paraganglioma in a young patient: conservative management by transurethral resection and diagnostic challenges.
    Pan Afr Med J. 2025;52:105.
    PubMed    
    Abstract available
    
    

91. WANG Y, Yuan H, Zhang Y, Zhang Y, et al
    Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer.
    Mater Today Bio. 2026;37:102835.
    PubMed    
    Abstract available
    
    

92. YU K, Sun J, Zhang J, Shi Y, et al
    Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer.
    Cancer Lett. 2026;642:218282.
    PubMed    
    Abstract available
    
    

93. ZHAO J, Zhao J, Huang W, Lin W, et al
    Decoding metabolic reprogramming heterogeneity across bladder cancer stages using single-cell and spatial multi-omics approaches.
    Comput Methods Programs Biomed. 2026;277:109261.
    PubMed    
    Abstract available
    
    

94. LI D, Lu J, Zhu R, Sun X, et al
    Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest.
    Tumour Virus Res. 2026;21:200337.
    PubMed    
    Abstract available
    
    

95. CHEN Z, Chen X, Xie R, Huang M, et al
    DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.
    Mol Ther. 2026 Jan 30:S1525-0016(26)00036-5. doi: 10.1016/j.ymthe.2026.
    PubMed    
    
    
    

96. DU A, Zhou Y, Deng X, Yuan D, et al
    DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6.
    Mol Cancer. 2026 Jan 30. doi: 10.1186/s12943-025-02560.
    PubMed    
    
    
    

97. DAY E, Bizzarri FP, Mackenzie C, Szabados B, et al
    Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.
    Nat Rev Urol. 2026 Jan 30. doi: 10.1038/s41585-026-01124.
    PubMed    
    Abstract available
    
    

98. MORIKAWA T, Hamamoto S, Tasaki Y, Ishikawa D, et al
    Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.
    Asian J Endosc Surg. 2026;19:e70248.
    PubMed    
    Abstract available
    
    

99. ZHOU J, Jiang X, Liu Q, Xia HA, et al
    PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.
    Cancer Metastasis Rev. 2026;45:7.
    PubMed    
    Abstract available
    
    

100. BOURGI A, Rusch E, Bruyere F
     Water-Related Exposures And Bladder Cancer Risk: A Comprehensive Epidemiological Review.
     Cancer Epidemiol Biomarkers Prev. 2026.
     PubMed    
     Abstract available
     
     

101. AY A, Alkanli N, Atli E, Gurkan H, et al
     Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression.
     Curr Issues Mol Biol. 2025;48:53.
     PubMed    
     Abstract available
     
     

102. RIAZ IB, Humayun MA, Khaki AR, Hussain SA, et al
     Treatment Sequencing in Advanced Urothelial Cancer.
     Drugs. 2026;86:203-215.
     PubMed    
     Abstract available
     
     

103. ZARZYCKA M, Kotula-Balak M, Gil D
     Inhibiting autophagy enhances anti-cancer properties of sulforaphane.
     Sci Rep. 2026;16:5296.
     PubMed    
     Abstract available
     
     

104. KIELBIK A, Hellwich E, Bahlinger V, Sowa P, et al
     Nanosecond pulsed electric fields induce cell-size-dependent selective permeabilization of urothelial cancer cells.
     Commun Biol. 2025;9:153.
     PubMed    
     Abstract available
     
     

105. KATSUMATA Y, Yamamoto S, Iwata H, Kuroiwa H, et al
     Agent-specific differences in sustained intraoperative hypotension during oral 5-Aminolevulinic acid-guided transurethral resection of bladder tumor: A retrospective observational study.
     Photodiagnosis Photodyn Ther. 2026;57:105319.
     PubMed    
     Abstract available
     
     

106. MANOHARAN M, Raja Iyub MJ, Zhang Y, Prabhakar P, et al
     Development of a Multivariable Machine Learning Model for the Prediction of Postoperative Ileus After Radical Cystectomy.
     J Surg Oncol. 2026;133:226-232.
     PubMed    
     Abstract available
     
     

107. WANG J, Zhao X, Jiang XL, Liu G, et al
     Construction and Validation of a Prognostic Survival Prediction Model for NMIBC Patients Undergoing Radical Cystectomy.
     Cancer Invest. 2026;44:156-173.
     PubMed    
     Abstract available
     
     

108. NIHARIKA, Tripathi S, Singhai A, Goel A, et al
     Clinical correlates of key autophagic markers, ATG4B, LC3 and p62 in urothelial carcinoma of bladder patients.
     Tissue Cell. 2026;99:103240.
     PubMed    
     Abstract available
     
     

109. TEOH JY, Bracco FM, Wong JH, Liu AQ, et al
     A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial.
     Eur Urol Oncol. 2026;9:111-115.
     PubMed    
     Abstract available
     
     

110. KONG L, Yang G, Weng B, Wen Z, et al
     Early Detection of Chemotherapy-Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium ((2)H) Metabolic Imaging: in Vitro and in Vivo Assessments.
     Adv Sci (Weinh). 2026;13:e14614.
     PubMed    
     Abstract available
     
     

111. RAGGI D, Crupi E, Pederzoli F, Martini A, et al
     HER2 and urothelial carcinoma: current understanding and future directions.
     Nat Rev Urol. 2026;23:110-132.
     PubMed    
     Abstract available
     
     

112. HARLE V, Agrawal YO
     Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.
     Curr Drug Targets. 2025;26:903-920.
     PubMed    
     Abstract available
     
     

113. FILON M, Schmidt B
     The Future of Novel Antibody-drug Conjugates in Localized Urothelial Cancer.
     Eur Urol Focus. 2026;12:34-37.
     PubMed    
     Abstract available
     
     

114. CHATZKEL J, Linscott J, Daniel Grass G, Li R, et al
     Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies.
     Eur Urol Focus. 2026;12:38-40.
     PubMed    
     Abstract available
     
     

115. WU K, Liu X, Zhang J, Wang X, et al
     Mechanisms and implications of epithelial cell plasticity in the bladder.
     Nat Rev Urol. 2026;23:70-88.
     PubMed    
     Abstract available
     
     

116. PYRGIDIS N, Schulz GB, Scilipoti P, Pellegrino F, et al
     The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis.
     Eur Urol Focus. 2026;12:88-95.
     PubMed    
     Abstract available
     
     

117. ROBBRECHT DGJ, Salhi Y, Martens JWM, Aarts MJB, et al
     Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.
     Eur Urol Oncol. 2026;9:7-11.
     PubMed    
     Abstract available
     
     

118. CHEN J, Fu S, Yu J, Tang Q, et al
     Modified Glasgow prognostic score as a marker for predicting outcomes in patients with either bladder and prostate cancer : A systematic review and meta-analysis.
     Oncology. 2025 Mar 28:1-20. doi: 10.1159/000545001.
     PubMed    
     Abstract available
     
     

119. HILSER T, Darr C, Bedke J, Ivanyi P, et al
     Treatment of Advanced or Metastatic Urothelial Cancer.
     Oncol Res Treat. 2026;49.
     PubMed    
     Abstract available
     
     

120. DOMIAN N, Mlynarczyk G, Kasacka I
     Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low- and High-Grade Papillary Urothelial Carcinoma.
     Cancer Med. 2026;15:e71649.
     PubMed    
     Abstract available
     
     

121. RYOO SW, Choi BY, Son SY, Lee JH, et al
     Occupational Exposure to Welding Fumes and the Risk of Bladder Cancer: A Systematic Review and Meta-Analysis.
     Am J Ind Med. 2026 Feb 15. doi: 10.1002/ajim.70062.
     PubMed    
     Abstract available
     
     

122. TUNCEKIN A, Aktas Y
     The role of systemic inflammatory and prognostic indices in diabetic patients with non-muscle invasive bladder cancer receiving BCG therapy.
     Actas Urol Esp (Engl Ed). 2026 Feb 12:501925. doi: 10.1016/j.acuroe.2026.501925.
     PubMed    
     Abstract available
     
     

123. MICHALET M, Ronchin P, Reynaud T, Demogeot N, et al
     Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.
     Radiother Oncol. 2026;217:111443.
     PubMed    
     Abstract available
     
     

124. GAO M, Li C, Li W, Xie J, et al
     White-to-brown adipose switching promotes bladder cancer progression.
     Neoplasia. 2026;73:101282.
     PubMed    
     Abstract available
     
     

125. SCILIPOTI P, Rosiello G, Santangelo A, Viti A, et al
     Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway.
     Urol Oncol. 2026;44:111007.
     PubMed    
     Abstract available
     
     

126. ELSAWY AA, Laymon M, Ezzat O, Mansour I, et al
     Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial.
     Urol Oncol. 2026;44:111006.
     PubMed    
     Abstract available
     
     

127. SONG YX, Xia XL, Wu ZM, Yao Y, et al
     Integration of bulk and single-cell transcriptomic sequencing reveals the neutrophil heterogeneity in bladder cancer and establishes a prognostic model.
     Discov Oncol. 2026 Feb 14. doi: 10.1007/s12672-026-04559.
     PubMed    
     
     
     

128. DINCER E, Ozkaptan O, Canakci C, Ipek OM, et al
     The Modified Frailty Index-5 as a Predictor of Postoperative Complications Following Radical Cystectomy.
     J Coll Physicians Surg Pak. 2026;36:258-262.
     PubMed    
     Abstract available
     
     

129. LIU Y, Duan L, Zhu M, Zhou Z, et al
     Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.
     BMC Complement Med Ther. 2026 Feb 13. doi: 10.1186/s12906-026-05279.
     PubMed    
     
     
     

130. WAN E, Wade C, Sathe A, Ferguson JE 3rd, et al
     Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.
     Curr Urol Rep. 2026;27:13.
     PubMed    
     Abstract available
     
     

131. SJODAHL G, Eriksson P, Hoglund M
     Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014.
     Eur Urol Focus. 2026 Feb 12:S2405-4569(26)00012.
     PubMed    
     
     
     

132. LIU J, Luo Y, Chen L, Xiong W, et al
     Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer.
     Biochim Biophys Acta Mol Basis Dis. 2026;1872:168192.
     PubMed    
     Abstract available
     
     

133. HUANG X, Chen R, Guo Z, Song C, et al
     Intensive nursing interventions for post-treatment anxiety and depression in bladder cancer: A systematic review and meta-analysis.
     Support Care Cancer. 2026;34:195.
     PubMed    
     Abstract available
     
     

134. LIU ZX, Shi YY, Zhou DS, Chen SN, et al
     Role of MED15 in Enhancing EMT and Metastasis in Bladder Cancer Through YAP1 Stabilization.
     FASEB J. 2026;40:e71558.
     PubMed    
     Abstract available
     
     

135. LI A, Zhao K, Wang T, Shi G, et al
     Transcriptome and single-cell RNA sequencing analysis with 101 machine learning combinations and experimental verification reveals the mechanism of action of mannose metabolism in bladder cancer.
     Front Immunol. 2026;17:1710823.
     PubMed    
     Abstract available
     
     

136. ZHANG G, Wang L, Zhao G, Huang Y, et al
     Hypoxia-Induced TGFBI Promotes Bladder Cancer Progression by Creating a Stemness Regulation Loop through Stabilizing the Disulfide Bonds of GDF15.
     Research (Wash D C). 2026;9:1134.
     PubMed    
     Abstract available
     
     

137. SHANGGUAN W, Li W, Huang W, Wu J, et al
     FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization.
     Adv Sci (Weinh). 2026 Feb 13:e23256. doi: 10.1002/advs.202523256.
     PubMed    
     Abstract available
     
     

138. BUTT UA, De Biase D
     Correction: Butt, U.A.; De Biase, D. The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer. Int. J. Mol. Sci. 2025, 26, 10558.
     Int J Mol Sci. 2026;27:1521.
     PubMed    
     Abstract available
     
     

139. RUTZ J, Grein T, Laqua M, Benhassine K, et al
     Natural Isothiocyanates Block Adhesion and Invasion of Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
     Molecules. 2026;31:555.
     PubMed    
     Abstract available
     
     

140. KOCAK T, Ozbek YD, Bodur M, Yesil S, et al
     Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.
     J Clin Med. 2026;15:1247.
     PubMed    
     Abstract available
     
     

141. PENG Y, Wang H, Chen H, Jin Z, et al
     SAPCD2 Drives Bladder Cancer Progression by Stabilizing TANK and Engaging a CREB-PLAGL2 Feedback Loop to Sustain MAPK Signaling.
     Cancers (Basel). 2026;18:535.
     PubMed    
     Abstract available
     
     

142. DEL GIUDICE F, Santarelli V, Khan A, Gad M, et al
     Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions.
     Cancers (Basel). 2026;18:500.
     PubMed    
     Abstract available
     
     

143. WANG X, Guo J, Zhang R, Dong Y, et al
     Hypoxia-inducible factor 1alpha exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion.
     Sci Rep. 2026 Feb 12. doi: 10.1038/s41598-026-39635.
     PubMed    
     Abstract available
     
     

144. KUANG J, An Y, Zhang X, He Z, et al
     Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally.
     Biochim Biophys Acta Rev Cancer. 2026 Feb 10:189558.
     PubMed    
     Abstract available
     
     

145. YUTKIN V, Maalouf N, Gur C, Zini A, et al
     Targeting Bladder Cancer with Inactivated Uropathogenic E. coli: A Novel Alternative to BCG Immunotherapy.
     Cells. 2026;15:229.
     PubMed    
     Abstract available
     
     

146. YANG Y, Wang F, Ning W, Ding Y, et al
     CircRNA_103809/miR-516a/FBXL18 contributes to stemness and gemcitabine resistance of bladder cancer cells.
     Arch Med Sci. 2025;21:2766-2782.
     PubMed    
     Abstract available
     
     

147. XU X, Gu W, Zakeri MA, Chen YH, et al
     No genetic causal links detected between antihypertensive medications and bladder cancer: insights from a trans-ancestry, drug-target Mendelian randomization analysis.
     Arch Med Sci. 2025;21:2856-2863.
     PubMed    
     
     
     

148. KUMAR P, Alarid-Escudero F, Chiddarwar TV, Garibay-Trevino DU, et al
     Differences in Bladder Cancer Diagnosis by Demographic Factors: A Simulation Modeling Analysis.
     medRxiv [Preprint]. 2026 Feb 2:2026.01.30.26344972.
     PubMed    
     Abstract available
     
     

149. LOCATELLI I, Lorenzoni M, Venegoni C, Di Coste A, et al
     PD1-IL2v expands and induces effector CD8(+) TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.
     J Exp Clin Cancer Res. 2026 Feb 11. doi: 10.1186/s13046-026-03667.
     PubMed    
     
     
     

150. UTLU A, Aksakalli T, Celik F, Cinislioglu AE, et al
     HALP score as an independent prognostic biomarker for recurrence and progression in non-muscle-invasive bladder cancer: A retrospective cohort study.
     Surg Oncol. 2026;65:102357.
     PubMed    
     Abstract available
     
     

151. 
     Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
     N Engl J Med. 2026;394:728.
     PubMed    
     
     
     

152. KUNG TC, Jiang YH, Kuo HC
     Prognostic factors for the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancer in Eastern Taiwan.
     Tzu Chi Med J. 2025;38:83-89.
     PubMed    
     Abstract available
     
     

153. LI L, Li Q, Liu J, Wang Y, et al
     Integrated single-cell and spatial transcriptomics combined with whole-exome sequencing reveal key hub genes and epithelial heterogeneity in bladder cancer.
     Front Oncol. 2026;15:1748105.
     PubMed    
     Abstract available
     
     

154. CASALE P, Hurle R, Buffi NM, Lughezzani G, et al
     Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study.
     Curr Urol. 2026;20:117-124.
     PubMed    
     Abstract available
     
     

155. SUN X, Jia D, Song X, Jiang Y, et al
     Revealing the function and mechanism of piRNA-related genes in bladder cancer through single-cell sequencing and methylation analyses and construction of prognostic features based on consensus clustering.
     Curr Urol. 2026;20:101-116.
     PubMed    
     Abstract available
     
     

156. HARLAND N, Reitnauer LE, Amend B, Bahlinger V, et al
     Significant differences in CD276 (B7H3) expression between female and male bladder cancer tissue samples: An exploratory study.
     Curr Urol. 2026;20:125-126.
     PubMed    
     
     
     

157. LIN N, Chen L, Zhang Y, Yang Y, et al
     Retraction Note: KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment.
     Sci Rep. 2026;16:5741.
     PubMed    
     
     
     

158. AYDOGDU C, McSweeney ST, Packiam VT, Bukavina L, et al
     ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.
     Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19129.
     PubMed    
     Abstract available
     
     

159. SORENSEN EE, Frydendahl A, Rasmussen MH, Nordentoft I, et al
     Molecular residual disease assessment in colorectal and bladder cancer by somatic structural variant analysis of cell-free DNA whole-genome sequencing data.
     J Transl Med. 2026 Feb 9. doi: 10.1186/s12967-026-07762.
     PubMed    
     
     
     

160. TAO L, Zhao T, Xu Y, Chen W, et al
     Integrative multi-cohort analysis identifies urinary microbiota as non-invasive biomarkers of bladder cancer.
     BMC Microbiol. 2026 Feb 9. doi: 10.1186/s12866-026-04829.
     PubMed    
     
     
     

161. LIN Z, Zhao K, Wang S, Liu J, et al
     Oncogenic and immunological roles of LAMP5 across cancers and its potential utility in bladder cancer.
     Apoptosis. 2026;31:65.
     PubMed    
     Abstract available
     
     

162. FUKUSHIMA H, Yoshida S, Yajima S, Chen W, et al
     A multi?criteria decision analysis comparing robot?assisted, laparoscopic, and open radical cystectomy using large-scale Japanese nationwide databases.
     J Robot Surg. 2026;20:230.
     PubMed    
     Abstract available
     
     

163. LEEDER M, Leucht K, Marx M, Grimm MO, et al
     [Treatment of non-muscle-invasive bladder cancer].
     Urologie. 2026 Feb 9. doi: 10.1007/s00120-026-02781.
     PubMed    
     Abstract available
     
     

164. GAO C, Cao X, Miao L, Chen W, et al
     lncRNA FENDRR as a Prognostic Biomarker and Regulator of Bladder Cancer Progression via the miR-18a-5p/ESR1 Axis.
     J Environ Pathol Toxicol Oncol. 2026;45:1-12.
     PubMed    
     Abstract available
     
     

165. LIU Q, Huang J
     ASO Author Reflections: Augmenting Contrast-Enhanced Ultrasound: A Quantitative Approach to Predict Muscle-Invasive Bladder Cancer.
     Ann Surg Oncol. 2026 Feb 9. doi: 10.1245/s10434-026-19236.
     PubMed    
     
     
     

166. MANIVASAGAM SS, Kassim A, Raman JD
     Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.
     Future Sci OA. 2026;12:2622297.
     PubMed    
     Abstract available
     
     

167. SHIBEL PE, Elyamany AM, El Shorbagy G, Abd Elmaogod EA, et al
     Exploring the Role Of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1.
     Asian Pac J Cancer Prev. 2026;27:667-675.
     PubMed    
     Abstract available
     
     

168. ABDEL-HAKEEM SS, Abdel-Hakeem SS, Kamal FMM
     Crosstalk between ZEB1 expression and CD163+ Tumor-Associated Macrophages in Muscle-Invasive Urothelial Carcinoma.
     Asian Pac J Cancer Prev. 2026;27:499-507.
     PubMed    
     Abstract available
     
     

169. CARAPITO A, Sousa TV, Teixeira-Marques A, Henrique R, et al
     Urinary Metabolomics Identifies Lactate as a Biomarker for Bladder Cancer Detection and Progression.
     Mol Omics. 2026 Feb 9:aaiag004. doi: 10.1093.
     PubMed    
     Abstract available
     
     

170. ROLLIN P, Pluskwa B, Artru E, Le Vaslot T, et al
     BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4(+) Th1 responses.
     iScience. 2026;29:114676.
     PubMed    
     Abstract available
     
     

171. LONCA L, Beniac P, Necsulescu A, Teixeira-Guerra D, et al
     Robot-Assisted Cystoprostatectomy for Muscle-Invasive Bladder Cancer in a Patient With a Prior Simultaneous Pancreas-Kidney Transplantation.
     Case Rep Transplant. 2026;2026:9534770.
     PubMed    
     Abstract available
     
     

172. ZHANG X, Su S, Liu L, Song F, et al
     Preoperative fibrinogen-to-lymphocyte ratio as a prognostic biomarker for non-muscle-invasive bladder cancer.
     Front Oncol. 2026;16:1707696.
     PubMed    
     Abstract available
     
     

173. SOOD A, Martini A, Rudzinski JK, Tholomier C, et al
     Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer.
     bioRxiv [Preprint]. 2026 Jan 26:2026.01.23.701130.
     PubMed    
     Abstract available
     
     

174. JIA B, Rao B, Chen R, Cui K, et al
     Overview of tumor-resident intratumoral microbiota in human bladder cancer.
     Transl Androl Urol. 2026;15:19.
     PubMed    
     Abstract available
     
     

175. ZHOU H, Ge Z, Lin S, Wu Y, et al
     Application of serum miRNA panel in bladder cancer detection.
     Transl Androl Urol. 2026;15:23.
     PubMed    
     Abstract available
     
     

176. ZHAO L, Yang JW, Chen SY, Wang L, et al
     Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.
     Transl Androl Urol. 2026;15:29.
     PubMed    
     Abstract available
     
     

177. ZHANG X, Fu Y, Du Y, Xiong W, et al
     CCT5 as a candidate biomarker in bladder cancer: functional validation and mechanistic clues.
     Am J Cancer Res. 2026;16:51-69.
     PubMed    
     Abstract available
     
     

178. RANJITH N, Khan PA, Koppolu S, Pavani S, et al
     Impact of lifestyle factors on recurrence rates in non-muscle invasive bladder cancer: A case-control study.
     Bioinformation. 2025;21:4025-4027.
     PubMed    
     Abstract available
     
     

179. WANG Y, Liu L, Li M
     Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report.
     Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:2031-2037.
     PubMed    
     Abstract available
     
     

180. ABU-GHANEM Y, Laszkiewicz J, Chan HT, Krajewski W, et al
     Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: A systematic review.
     Crit Rev Oncol Hematol. 2026;220:105192.
     PubMed    
     Abstract available
     
     

181. KLINGLMAIR G, Lutz M, Telia T, van Creij NCH, et al
     Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.
     J Nutr Health Aging. 2026;30:100805.
     PubMed    
     Abstract available
     
     

182. XIE H, Liao T, Tang H, Ban C, et al
     The GFPT2/O-GlcNAcylation/c-Myc axis promotes bladder cancer progression.
     J Transl Med. 2026 Feb 7. doi: 10.1186/s12967-026-07811.
     PubMed    
     
     
     

183. CONTIERI R, Paciotti M, Uleri A, Saita A, et al
     Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial.
     Eur Urol Oncol. 2026 Feb 6:S2588-9311(26)00031-3. doi: 10.1016/j.euo.2026.
     PubMed    
     Abstract available
     
     

184. DEMIGNE JB, Ferber E, Rodrigues M, Flippot R, et al
     [Perioperative durvalumab with neoadjuvant cisplatine-gemcitabine chemotherapy in localized muscle-invasive bladder cancer].
     Bull Cancer. 2026 Feb 6:S0007-4551(26)00056-1. doi: 10.1016/j.bulcan.2025.
     PubMed    
     
     
     

185. GARG T, Negron-Candelario S, Miller H, Demirsoy S, et al
     Adapting patient priorities care for older adults with non-muscle-invasive bladder cancer: A qualitative inquiry.
     Urol Oncol. 2026;44:110996.
     PubMed    
     Abstract available
     
     

186. QIN M, Xie G, Xie H, Lin B, et al
     Development and validation of a novel senescence-associated gene signature for prediction of survival and endocrine-disrupting chemicals in bladder cancer.
     Discov Oncol. 2026 Feb 7. doi: 10.1007/s12672-026-04611.
     PubMed    
     
     
     

187. CHEN H, Peng Y, Ji Z, Dong J, et al
     SPP1(+) Macrophage-POSTN(+) Fibroblast-Endothelial Triad Dictates Immunotherapy Response in Bladder Cancer.
     FASEB J. 2026;40:e71546.
     PubMed    
     Abstract available
     
     

188. KONG Y, Li Y, An M, Luo Y, et al
     Correction: ZEB1-mediated biogenesis of circnipbl sustains the metastasis of bladder cancer via Wnt/beta-catenin pathway.
     J Exp Clin Cancer Res. 2026;45:39.
     PubMed    
     
     
     

189. ZHANG Q, Guo Y, Lin F, Zuo Y, et al
     ?CT image-derived radiomics predicts molecular subtypes in bladder urothelial carcinoma: validation of a non-invasive classification strategy.
     Sci Rep. 2026;16:6016.
     PubMed    
     Abstract available
     
     

190. HERCZEG BT, Sudar A, Ortutay R, Agoston P, et al
     Risk estimations of radiation induced malignancies in rectum and bladder following radiotherapy of prostate carcinoma.
     Phys Med. 2026;142:105714.
     PubMed    
     Abstract available
     
     

191. JENDEBERG J, Bjorkman A, Dahlman P, Eklof H, et al
     Computed tomography urography in macroscopic hematuria: a retrospective study with implications for standard care pathway.
     Acta Radiol. 2026;67:227-236.
     PubMed    
     Abstract available
     
     

192. ZHU Y, Jiang S, Shi Y, Wang S, et al
     Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
     Ann Oncol. 2026;37:378-387.
     PubMed    
     Abstract available
     
     

193. IWATANI K, Urabe F, Mori K, Nakano J, et al
     Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.
     Jpn J Clin Oncol. 2026;56:234-240.
     PubMed    
     Abstract available
     
     

194. YAJIMA S, Yoshida S, Chen W, Hirose K, et al
     Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trial.
     Jpn J Clin Oncol. 2026;56:216-220.
     PubMed    
     Abstract available
     
     

195. ESCOBAR D, Doshi C, Zahir M, Daneshmand S, et al
     Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder.
     Urologie. 2026;65:162-170.
     PubMed    
     Abstract available
     
     

196. BAHLBURG H, Rausch P, Tully KH, Berg S, et al
     Psychosocial distress after radical prostatectomy, radical cystectomy, or (partial) nephrectomy - a comprehensive analysis of 4,290 German cancer patients during the COVID-19 pandemic.
     J Cancer Surviv. 2026;20:181-188.
     PubMed    
     Abstract available
     
     

197. LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
     Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes.
     Eur Urol Oncol. 2026 Feb 19:S2588-9311(26)00042.
     PubMed    
     Abstract available
     
     

198. GAO J, Pan Y, Cheng Q, Wang S, et al
     USP43 promotes lymphatic metastasis of bladder cancer by regulation of ZBTB7A.
     Cell Signal. 2026 Feb 18:112433. doi: 10.1016/j.cellsig.2026.112433.
     PubMed    
     Abstract available
     
     

199. JONAS K, Moser T, Heitzer E
     Listening to the bladder field: Urine liquid biopsies reveal differential treatment responses in NMIBC.
     Cell. 2026;189:995-997.
     PubMed    
     Abstract available
     
     

200. ZHANG H, Han S, Su Z, Zheng Z, et al
     Single-cell transcriptomic analysis and machine learning identify ATAD3A as a key gene that stabilizes mitochondrial-endoplasmic reticulum membranes, promoting bladder cancer progression.
     J Transl Med. 2026 Feb 20. doi: 10.1186/s12967-026-07857.
     PubMed    
     Abstract available
     
     

201. KWON J, Jeon J, Lee HS, Jeon S, et al
     Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population.
     World J Mens Health. 2026 Jan 15. doi: 10.5534/wjmh.250298.
     PubMed    
     Abstract available
     
     

202. LAHIRI A, Chowdhury S, Goel S, Assif Iqbal S, et al
     Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study.
     HPB (Oxford). 2026 Feb 2:S1365-182X(26)00016-X. doi: 10.1016/j.hpb.2026.
     PubMed    
     Abstract available
     
     

203. CAUSIO FA, De Vita V, Nappi A, Sawaya M, et al
     Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study.
     JMIR Perioper Med. 2026;9:e86666.
     PubMed    
     Abstract available
     
     

204. KATO M, Matsue T, Yamamoto S, Yukimatsu N, et al
     Clinical impact of carboplatin-based neoadjuvant chemotherapy: lack of benefit and surgical delay in muscle-invasive bladder cancer.
     Jpn J Clin Oncol. 2026 Feb 19:hyag027. doi: 10.1093.
     PubMed    
     Abstract available
     
     

205. ZHANG P, Xiong W, Wang K, Zhao X, et al
     Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects.
     Nanoscale. 2026 Feb 19. doi: 10.1039/d5nr04072.
     PubMed    
     Abstract available
     
     

206. LIU X, Chen Z, Lu Y, Wu Y, et al
     Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.
     Front Microbiol. 2026;17:1756107.
     PubMed    
     Abstract available
     
     

207. OKADA N, Kimura H, Ozaki M, Tamura M, et al
     Risk Factor of Persistent Hypotension Associated with 5-Aminolevulinic Acid: A Single-Institution Retrospective Study.
     Biol Pharm Bull. 2026;49:335-340.
     PubMed    
     Abstract available
     
     

208. SUN Y, Tong H, Zhao G, Wu L, et al
     Nutrient Deprivation Promotes Bladder Cancer Metastasis through Beclin-1 Deacetylation-Mediated Autophagy Activation.
     Cancer Lett. 2026 Feb 16:218337. doi: 10.1016/j.canlet.2026.218337.
     PubMed    
     Abstract available
     
     

209. VULSTEKE C, Adra N, Danchaivijitr P, Sabadash M, et al
     Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
     N Engl J Med. 2026 Feb 18. doi: 10.1056/NEJMoa2511674.
     PubMed    
     Abstract available
     
     

210. XU C, Dong Y, Li J, Liao X, et al
     Integrating machine learning and mendelian randomization for identifying genetic biomarkers in bladder cancer: implications for early diagnosis and targeted therapies.
     Int J Surg. 2025 Dec 3. doi: 10.1097/JS9.0000000000003833.
     PubMed    
     Abstract available
     
     

211. HU J, Zhu Y, Wang G, Dai H, et al
     SNW1 promotes lymphatic metastasis in bladder cancer by modulating SRPK1 splicing.
     iScience. 2026;29:114811.
     PubMed    
     Abstract available
     
     

212. HUANG X, Meng Y, Song J, Zhu Y, et al
     KNSTRN knockdown impairs autophagy flux to inhibit bladder cancer progression.
     iScience. 2026;29:114734.
     PubMed    
     Abstract available
     
     

213. ZHANG J, Wang J, Hu X, Jia W, et al
     Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.
     iScience. 2026;29:114786.
     PubMed    
     Abstract available
     
     

214. HINLEY J, Baker SC, Mason AS, Kyriazis G, et al
     Connexin 32 constrains a mesenchymal-like switch in differentiated urothelium and luminal cancers.
     Life Sci Alliance. 2026;9:e202503427.
     PubMed    
     Abstract available
     
     

215. KOHLER J, Buck L, Hugelmann K, Incesu RB, et al
     Chronological and biological age stratify survival after robot-assisted radical cystectomy for bladder cancer: a pragmatic age-ECOG risk score.
     World J Urol. 2026;44:178.
     PubMed    
     Abstract available
     
     

216. ACCETTO T, Strasek Smrdel K, Taskovska M, Starcic Erjavec M, et al
     Negative-control-anchored urinary microbiome profiling with absolute 16S quantification: a pilot study in newly diagnosed, treatment-naive bladder cancer and healthy individuals.
     FEMS Microbiol Lett. 2026 Feb 17:fnag020. doi: 10.1093.
     PubMed    
     Abstract available
     
     

217. LIU Q, Lu X, He C, Chen J, et al
     Correction: A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
     Ann Surg Oncol. 2026 Feb 16. doi: 10.1245/s10434-026-19331.
     PubMed    
     
     
     

218. LI H, Long G, Hu L, Wang Q, et al
     Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: a multicenter, prospective single-arm cohort.
     Photodiagnosis Photodyn Ther. 2026 Feb 14:105396.
     PubMed    
     Abstract available
     
     

219. CRESTANI B, Tamborrino V, Bertolo R, Antonelli A, et al
     Balancing maternal and fetal safety in non-muscle-invasive bladder cancer: report of our experience.
     Minerva Urol Nephrol. 2026;78:155-157.
     PubMed    
     
     
     

220. LAMBERTINI L, Saladino M, DI Maida F, Grosso AA, et al
     Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience.
     Minerva Urol Nephrol. 2026;78:118-126.
     PubMed    
     Abstract available
     
     

221. CHEN KY, Jones MK, Ghosal S, Ignozzi GP, et al
     Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer.
     BJUI Compass. 2026;7:e70135.
     PubMed    
     Abstract available
     
     

222. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
     Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.
     BJUI Compass. 2026;7:e70173.
     PubMed    
     Abstract available
     
     

223. INDRASWARI MT, Rahman F, Hamid ARAH, Mochtar CA, et al
     Psychological distress among bladder cancer patients: A systematic review.
     Urol Ann. 2026;18:10-17.
     PubMed    
     Abstract available
     
     

224. SONG F, Su S, Zhang X, Cao Y, et al
     A nomogram based on the red cell distribution width to lymphocyte ratio as a prognostic tool for non-muscle-invasive bladder cancer: a retrospective study.
     Front Oncol. 2026;16:1728821.
     PubMed    
     Abstract available
     
     

225. PAN S, Zhu H, Yin R, Lin J, et al
     Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.
     Front Cell Infect Microbiol. 2026;15:1727550.
     PubMed    
     Abstract available
     
     

226. BASAR M, Yol C, Chen JF, Al-Ahmadie H, et al
     Micropapillary Urothelial Carcinoma: A Review and Update.
     Adv Anat Pathol. 2026;33:e1-e8.
     PubMed    
     Abstract available
     
     

227. DAS M, Rath S, Gorepatti R, Dash R, et al
     Microbiome-linked transcriptomic signatures in NMIBC: Toward personalized uro-oncology.
     Urol Oncol. 2026;44:110977.
     PubMed    
     Abstract available
     
     

228. QU M, Wei J, Mo J, Chen J, et al
     Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.
     Urol Oncol. 2026;44:110970.
     PubMed    
     Abstract available
     
     

229. WEIR S, Murgas KA, Froehlich M, Nash M, et al
     Urothelial cell carcinoma of the bladder in pediatric patients: A comparison with adults from the National Cancer Database.
     J Pediatr Urol. 2026;22:105677.
     PubMed    
     Abstract available
     
     

230. WEBER TD, Gershman B, Wang L, Rosen S, et al
     Rapid evaluation of muscularis propria in transurethral resection of bladder tumour specimens using non-linear microscopy (NLM).
     J Clin Pathol. 2026;79:186-191.
     PubMed    
     Abstract available
     
     

231. LANGE F, Gaisa NT, Bolenz C, Klumper N, et al
     [Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making].
     Aktuelle Urol. 2026;57:52-59.
     PubMed    
     Abstract available
     
     

232. NIEGISCH G, Zschabitz S, Klumper N, Eckstein M, et al
     [Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology].
     Aktuelle Urol. 2026;57:46-51.
     PubMed    
     Abstract available
     
     

233. AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
     Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
     BJU Int. 2026;137:536-546.
     PubMed    
     Abstract available
     
     

234. BHATTACHARYA R, Kponee-Shovein K, Gao Y, Song Y, et al
     Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases.
     Cancer. 2026;132:e70220.
     PubMed    
     Abstract available
     
     

235. LUO W, Wang Y, Wang H, Ji YA, et al
     CCL5hi-CD4+ T cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.
     Cancer Res. 2026 Feb 18. doi: 10.1158/0008-5472.CAN-25-2220.
     PubMed    
     Abstract available
     
     

236. EPSTEIN IB, Odogiyon A, Berg S, Otani Y, et al
     ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.
     Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-3712.
     PubMed    
     Abstract available
     
     

237. GUERCIO BJ, Pietzak EJ, Ravichandran V, Chen JF, et al
     Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.
     Clin Cancer Res. 2026 Feb 2. doi: 10.1158/1078-0432.CCR-25-3771.
     PubMed    
     Abstract available
     
     

238. MIRKHESHTI N, Kpormegbey DE, Weinstock C, Gao X, et al
     FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer.
     Clin Cancer Res. 2026 Feb 12. doi: 10.1158/1078-0432.CCR-25-3609.
     PubMed    
     Abstract available
     
     

239. KATIMS AB, White C, Alam SM, Farha M, et al
     Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
     Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-3395.
     PubMed    
     Abstract available
     
     

240. LOPEZ-BELTRAN A, Cimadamore A, Blanca A, Montironi R, et al
     Sarcomatoid urothelial carcinoma: advances and challenges.
     Curr Opin Urol. 2026;36:147-154.
     PubMed    
     Abstract available
     
     

241. COMPERAT E
     Biomarkers and testing in pathology.
     Curr Opin Urol. 2026;36:212-216.
     PubMed    
     Abstract available
     
     

242. ERTOY-BAYDAR D
     Histologic subtypes of urothelial carcinoma: an update.
     Curr Opin Urol. 2026;36:138-146.
     PubMed    
     Abstract available
     
     

243. REIS H, Szarvas T, Paner GP
     Urachal cancer: a clinical, diagnostic, and therapeutic update.
     Curr Opin Urol. 2026;36:155-160.
     PubMed    
     Abstract available
     
     

244. ST-LAURENT MP, Black PC
     The challenge of bladder preservation in muscle invasive bladder cancer: key concepts and future directions.
     Curr Opin Urol. 2026 Jan 30. doi: 10.1097/MOU.0000000000001369.
     PubMed    
     Abstract available
     
     

245. PERRI D, Roche JB, Petrut B, Bozzini G, et al
     Bladder diverticula management - conservative and surgical outcomes: a narrative review from EAU endourology.
     Curr Opin Urol. 2026;36:79-85.
     PubMed    
     Abstract available
     
     

246. CABRERA C, Buisan O, Servian P
     Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
     Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

247. PICHLER R, Subiela JD, Guerrero-Ramos F
     Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
     Eur Urol. 2026 Feb 4:S0302-2838(26)00054-0. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

248. GABRIEL PE, Xylinas E
     Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5.
     Eur Urol. 2026 Feb 3:S0302-2838(26)00030-8. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

249. BABJUK M
     Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial.
     Eur Urol. 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

250. HAYNE D, Zhang AY, Thomas H, Krieger L, et al
     Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
     Eur Urol. 2026 Feb 2:S0302-2838(26)00015-1. doi: 10.1016/j.eururo.2026.
     PubMed    
     Abstract available
     
     

251. TATEO V, Basile G, Giannatempo P, de Jong JJ, et al
     Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
     Eur Urol. 2026 Feb 2:S0302-2838(26)00022-9. doi: 10.1016/j.eururo.2026.
     PubMed    
     Abstract available
     
     

252. MYERS AA, Talwar R, Duan Z, Hensley P, et al
     Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guerin-unresponsive Carcinoma in Situ of the Bladder.
     Eur Urol. 2026;89:151-162.
     PubMed    
     Abstract available
     
     

253. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
     Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].
     Eur Urol. 2026 Feb 17:S0302-2838(26)00063-1. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

254. SHIMIZU S, Osawa T, Sato M, Yamada S, et al
     Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
     Int J Urol. 2026;33:e70364.
     PubMed    
     Abstract available
     
     

255. FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
     Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
     Int J Urol. 2026;33:e70283.
     PubMed    
     Abstract available
     
     

256. ABE Y, Taoka R, Kaji A, Harada S, et al
     Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.
     Int J Urol. 2026;33:e70365.
     PubMed    
     Abstract available
     
     

257. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
     Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
     Int J Urol. 2026;33:e70380.
     PubMed    
     
     
     

258. KUSANO S, Tobu S, Yukimoto M, Yamaguchi Y, et al
     Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care.
     Int J Urol. 2026;33:e70386.
     PubMed    
     Abstract available
     
     

259. OZDEN SB, Bulbul E, Ilki Y, Vural A, et al
     Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.
     Int Urol Nephrol. 2026 Jan 26. doi: 10.1007/s11255-026-05021.
     PubMed    
     Abstract available
     
     

260. AYKAC A, Kaya C, Sungur M, Aydin ME, et al
     Holmium laser en?bloc vs bipolar and conventional monopolar TURBT for non?muscle?invasive bladder cancer.
     Int Urol Nephrol. 2026 Jan 24. doi: 10.1007/s11255-026-05023.
     PubMed    
     Abstract available
     
     

261. REZAEE ME, Higgins MI, Su ZT, Sepehri S, et al
     Results from the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial.
     J Urol. 2026 Feb 9:101097JU0000000000004983. doi: 10.1097/JU.0000000000004983.
     PubMed    
     Abstract available
     
     

262. ANDERSON CB, Sfakianos JP
     Circulating Tumor DNA in Bladder Cancer: A New Treatment Paradigm?
     J Urol. 2026;215:256-257.
     PubMed    
     
     
     

263. LAZAROVICH A, Nusbaum DJ, Agarwal PK, Modi PK, et al
     Clinical Trial Design for Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer-Single-Arm Design Was Necessary, Randomized Trials Are Now Essential.
     J Urol. 2026 Feb 11:101097JU0000000000004960. doi: 10.1097/JU.0000000000004960.
     PubMed    
     
     
     

264. ZHAO D, Khatri VM, Nakashima JY, Chadha J, et al
     Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy.
     J Urol. 2026;215:305-315.
     PubMed    
     Abstract available
     
     

265. ELIAS R, Aragaki AK, Hoffman-Censits JH, Hahn NM, et al
     Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
     J Urol. 2026;215:294-304.
     PubMed    
     Abstract available
     
     

266. RITCH C, Anderson CB
     Cystoscopic Fulguration for Patients with Recurrent Low-Grade Bladder Cancer.
     J Urol. 2026 Feb 18:101097JU0000000000004974. doi: 10.1097/JU.0000000000004974.
     PubMed    
     
     
     

267. ZHANG S, Li T, Li D, Yin Y, et al
     Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.
     J Urol. 2026 Feb 17:101097JU0000000000004993. doi: 10.1097/JU.0000000000004993.
     PubMed    
     Abstract available
     
     

268. WANG J, Wang J, Meng L, Wang X, et al
     Interstitial cystitis-related gene CCDC8 accelerates tumorigenesis by participating in CUL7-mediated degradation of P53 in bladder cancer.
     Oncogene. 2026 Feb 5. doi: 10.1038/s41388-026-03688.
     PubMed    
     Abstract available
     
     

269. SIGUENCIA F, Heard J, Smith SM, Pagano I, et al
     Diagnostic performance of urinary biomarker tests in detecting bladder cancer: A systematic review, meta-analysis, and network meta-analysis.
     Urology. 2026 Feb 4:S0090-4295(26)00074-9. doi: 10.1016/j.urology.2026.
     PubMed    
     Abstract available
     
     

270. SMITH AB, Gore JL, Chisolm S, Squires P, et al
     Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
     Urology. 2026 Feb 11:S0090-4295(26)00092-0. doi: 10.1016/j.urology.2026.
     PubMed    
     Abstract available
     
     

271. HJORT PB, Hyldgaard JM, Young-Halvorsen K, Husch T, et al
     Association between Photodynamic diagnosis and risk of recurrence and progression in BCG-treated non-muscle invasive bladder cancer patients: a nationwide follow-up study.
     Urology. 2026 Feb 10:S0090-4295(26)00091-9. doi: 10.1016/j.urology.2026.
     PubMed    
     Abstract available
     
     

272. APONTE-COLON DA, Wilcox Vanden Berg R, Tua-Caraccia R, Kim JK, et al
     Clinical Characteristics, Recurrence, and Survival for Children and Young Adults With Urothelial Cancer: A Systematic Review.
     Urology. 2026;208:135-141.
     PubMed    
     Abstract available
     
     

273. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
     Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
     BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
     PubMed    
     
     
     

274. OSAKA K, Kishida T, Umemoto S, Karashima T, et al
     Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
     BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
     PubMed    
     
     
     

275. ZEBER-LUBECKA N, Bilski K, Dabrowska M, Goryca K, et al
     Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.
     BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15666.
     PubMed    
     Abstract available
     
     

276. GAO X, Yu Y, Sun J, Zhao H, et al
     CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy.
     PLoS Biol. 2026;24:e3003647.
     PubMed    
     Abstract available
     
     

277. FENG C, Chen G, Shu Y, Chen J, et al
     Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation.
     PLoS One. 2026;21:e0342162.
     PubMed    
     Abstract available
     
     

278. SHEN J, Zhao Z, Li Z, Wang R, et al
     Bladder cancer-induced CVD mortality: Role of CAPG protein.
     PLoS One. 2026;21:e0338101.
     PubMed    
     Abstract available
     
     

279. GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
     Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
     Proc Natl Acad Sci U S A. 2026;123:e2533449123.
     PubMed    
     Abstract available